March 2022 Publications
- Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case. Kochhar S, Barreira D, Beattie P, Cavaleri M, Cravioto A, Frick MW, Ginsberg AM, Hudson I, Kaslow DC, Kurtz S, Lienhardt C, Madhi SA, Morgan C, Momeni Y, Patel D, Rees H, Rogalski-Salter T, Schmidt A, Semete-Makokotlela B, Voss G, White RG, Zignol M, Giersing B. Vaccine. 2022 Mar 15. doi: 10.1016/j.vaccine.2021.10.062. Epub 2022 Feb 11.
- Correction to: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China. Weerasuriya CK, Harris RC, McQuaid CF, Bozzani F, Ruan Y, Li R, Li T, Rade K, Rao R, Ginsberg AM, Gomez GB, White RG. BMC Med. 2022 Mar 1. doi: 10.1186/s12916-022-02306-3.
- Challenges in Developing a Controlled Human Tuberculosis Challenge Model. Jackson S, McShane H. Curr Top Microbiol Immunol. 2022 Mar 25. doi: 10.1007/82_2022_252. Online ahead of print.
- The Mycobacterium tuberculosis PhoPR virulence system regulates expression of the universal second messenger c-di-AMP and impacts vaccine safety and efficacy. Pérez I, Campos-Pardos E, Díaz C, Uranga S, Sayes F, Vicente F, Aguiló N, Brosch R, Martín C, Gonzalo-Asensio J. Mol Ther
- Relevance of genomic diversity of Mycobacterium tuberculosis complex in Africa. Osei-Wusu S, Otchere ID, Asare P, Ntoumi F, Zumla A, Asante-Poku A, Yeboah-Manu D. Int J Infect Dis. 2022 Mar 20. doi: 10.1016/j.ijid.2022.03.016. Online ahead of print.
- Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine? Dockrell HM, Butkeviciute E. Vaccine. 2022 Mar 8. doi: 10.1016/j.vaccine.2021.01.068. Epub 2021 Feb 12.
- A novel peptide vaccination augments cytotoxic CD8(+) T-cell responses against Mycobacterium tuberculosis HspX antigen. Lew MH, Norazmi MN, Nordin F, Tye GJ. Immunobiology. 2022 Mar 5. doi: 10.1016/j.imbio.2022.152201. Online ahead of print.
- Conjugation with loxoribine and mannan improves the immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 fusion protein. Yu W, Shen L, Qi J, Hu T. Eur J Pharm Biopharm. 2022 Mar. doi: 10.1016/j.ejpb.2022.02.011. Epub 2022 Feb 18.
- Intervention hesitancy among healthcare personnel: conceptualizing beyond vaccine hesitancy. Gur-Arie R, Davidovitch N, Rosenthal A. Monash Bioeth Rev. 2022 Mar 20. doi: 10.1007/s40592-022-00152-w. Online ahead of print.
- Gene expression in TB disease measured from the periphery is different from the site of infection. Jobe D, Darboe F, Muefong CN, Barry A, Coker EG, Mohammed N, Jobe A, Davies MM, Faye B, Jallow R, Donkor S, Touray S, Owolabi O, Sutherland JS. Tuberculosis (Edinb). 2022 Mar 17. doi: 10.1016/j.tube.2022.102187. Online ahead of print.
- A place for neutrophils in the beneficial pathogen-agnostic effects of the BCG vaccine. Brook B, Schaltz-Buchholzer F, Ben-Othman R, Kollmann T, Amenyogbe N. Vaccine. 2022 Mar 8. doi: 10.1016/j.vaccine.2021.03.092. Epub 2021 Apr 15.
- Human lymph node immune dynamics as driver of vaccine efficacy: an understudied aspect of immune responses. Moysi E, Paris RM, Le Grand R, Koup RA, Petrovas C. Expert Rev Vaccines. 2022 Mar 9. doi: 10.1080/14760584.2022.2045198. Online ahead of print.
- The introduction of BCG vaccination to neonates in Northern Sweden, 1927-31: Re-analysis of historical data to understand the lower mortality among BCG-vaccinated children. Schaltz-Buchholzer F, Kjær Sørensen M, Benn CS, Aaby P. Vaccine. 2022 Mar 8. doi: 10.1016/j.vaccine.2021.06.006. Epub 2021 Jun 13.
- Protective Efficacy of BCG Vaccine against Mycobacterium leprae and Non-Tuberculous Mycobacterial Infections. Orujyan D, Narinyan W, Rangarajan S, Rangchaikul P, Prasad C, Saviola B, Venketaraman V. Vaccines (Basel). 2022 Mar 3. doi: 10.3390/vaccines10030390.
- Novel In Silico mRNA vaccine design exploiting proteins of M. tuberculosis that modulates host immune responses by inducing epigenetic modifications. Al Tbeishat H. Sci Rep. 2022 Mar 17. doi: 10.1038/s41598-022-08506-4.
- Development of peptide vaccine candidate using highly antigenic PE-PGRS family proteins to stimulate the host immune response against Mycobacterium tuberculosis H(37)Rv: an immuno-informatics approach. Kumar A, Sharma P, Arun A, Meena LS. J Biomol Struct Dyn. 2022 Mar 16. doi: 10.1080/07391102.2022.2048079. Online ahead of print.
- A New Intranasal Influenza Vector-Based Vaccine TB/FLU-04L Against Tuberculosis: Preclinical Safety Studies. Buzitskaya Z, Stosman K, Khairullin B, Kassenov M, Nurpeisova A, Abylai Sansyzbay A, Shurygina AP, Aleksandrov A, Sivak K, Stukova M. Drug Res (Stuttg). 2022 Mar 22. doi: 10.1055/a-1785-3936. Online ahead of print.
- Mycobacterium tuberculosis EspK Has Active but Distinct Roles in the Secretion of EsxA and EspB. Lim ZL, Drever K, Dhar N, Cole ST, Chen JM. J Bacteriol. 2022 Mar 22. doi: 10.1128/jb.00060-22. Online ahead of print.
- Characterization of O-mannosylated proteins profiling in bacillus Calmette-Guérin via gel-based and gel-free approaches. Zheng J, Liu L, Wei C, Liu B, Jin Q. IUBMB Life. 2022 Mar. doi: 10.1002/iub.2578. Epub 2021 Nov 25.